Introduction
DNA methylation refers to the chemical modification of the cytosine ring in a CpG dinucleotide by the addition of a methyl group (-CH3) to the number 5 carbon of the cytosine pyrimidine ring in the CpG dinucleotide, resulting in the formation of 5-methylcytosine [
1]. Global DNA hypomethylation, but aberrant, gene-specific DNA hypermethylation of the promoter-associated CpG islands of tumor suppressor genes (TSGs), is a hallmark of many human cancers [
2,
3]. Methylation of multiple TSGs has involved in the dysregulation of signaling pathways in leukemia, lymphoma and myeloma, including cell cycle (
CDKN2A/B), apoptosis (
DAPK1/
CDKN2A/
APAF1), JAK/STAT signaling and WNT signaling; thereby indicating the importance of TSGs methylation in the pathogenesis of hematological cancers [
4‐
6]. Of note, the DNA hypermethylation in TSGs, such as
DAPK1,
ID4,
SFRP1,
TWIST2 and
ZAP70, has been identified to play a role in the pathogenesis or prognosis of chronic lymphocytic leukemia (CLL) [
7‐
11].
Mature microRNA (miRNAs) are endogenous, single-stranded, non-protein-coding small RNAs measuring 19 to 25 nucleotides (nts), which suppress the expression of proteins that they target [
12,
13]. In carcinogenesis, miRNAs can be categorized into either oncogenic (oncomirs) or tumor suppressor miRNAs [
14,
15]. Recently, tumor suppressor miRNAs have shown to be silenced by aberrant DNA hypermethylation in cancers [
1,
16,
17]. Furthermore, previous studies also identified methylation of some tumor suppressor miRNAs, including
miR-203,
miR-124-1,
miR-181a/b,
miR-107 and
miR-424, to be involved in CLL leukemogenesis [
18].
In humans, there are three independent
miR-9 genes (
miR-9-1 on chromosome 1;
miR-9-2 on chromosome 5 and
miR-9-3 on chromosome 15), with identical mature
miR-9 sequence. In cancers,
miR-9 could be either oncomir or tumor suppressor miRNA, depending on the type of cancers or tissues [
19,
20]. For instance, overexpression of
miR-9 has been shown to enhance metastasis or invasion in breast cancer cells or glioblastoma, identifying its oncogenic role [
21‐
23]. Conversely,
miR-9 has been shown to target and repress NFκB1 translation in ovarian tumor cells by binding to the 3′ untranslated region (3′ UTR) of the
NFκB1 mRNA, leading to inhibition of cell proliferation; hence demonstrating a tumor suppressor function [
24].
In this report, we studied methylation of miR-9-3, in addition to miR-9-1 and miR-9-2 in a representative cohort of CLL to define its pathogenetic role.
Materials and methods
Patient samples
Bone marrow samples were obtained from 78 CLL patients at diagnosis. The diagnosis of CLL was made according to the WHO Classification, based on classical morphology, low level of expression of light-chain-restricted surface immunoglobulin, and concomitant expression of CD5 and CD23 as demonstrated by flow cytometry [
25,
26]. Of the 78 CLL patients, there were 51 male (65.4%) and 27 female (34.6%) patients at a median age of 65 years (range: 37–91 years). The median presenting lymphocyte count was 18 × 10
9/L (range: 10–540 × 10
9/L). Apart from 8 patients with insufficient Rai stage data, there were 42 (60.0%) limited Rai stage (<stage II) and 28 (40.0%) advanced Rai stage (≥stage II) patients. Among the 53 patients with cytogenetic information, 13 (24.5%) carried high/intermediate-risk cytogenetic aberrations [del(17p), N = 2; del(11q), N = 2; trisomy 12, N = 9] and 40 (75.5%) carried low/standard-risk cytogenetic alterations [del(13q), N = 12; normal karyotype, N = 21; other karyotypic changes, N = 7]. The median overall survival (OS) of this cohort was 69 months. The median OS of those with advanced Rai stage and limited Rai stage were 49 and 111 months respectively (P = 0.006). Furthermore, the median OS for those with or without high/intermediate-risk karyotype were 28 months and 111 months respectively (P = 0.003). Samples were obtained with written informed consent, and the study was approved by the Institutional Review Board of Queen Mary Hospital and in accordance with the Declaration of Helsinki.
Cell lines and culture
The human CLL cell lines CLL-AAT and MEC1 were purchased from American Type Culture Collection (Manassas, USA) and Deutsche Sammlung von Mikroorganismen und Zellkulturen Deutsche GmbH (DMSZ) (Braunschweig, Germany) respectively. MEC2, I83-E95 and WAC3CD5+ were kindly provided by Dr John C. Byrd, Department of Medicine, Ohio State University [
27,
28]. HG3 and 232B4 were kind gifts from Prof. Anders Rosén, Department of Clinical & Experimental Medicine, Linköping University [
28,
29]. Cell cultures were maintained in RPMI medium 1640, supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) in a humidified atmosphere of 5% CO
2 at 37°C.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from seventy-eight bone marrow samples of CLL at diagnosis, seven cell lines and eight normal controls (CD19 sorted peripheral blood B cells from healthy donors, N = 3; peripheral blood buffy coats from healthy donors, N = 2; and bone marrow buffy coats from healthy donors, N = 3) by the QIAamp DNA Blood Mini Kit (QIAGEN, Germany). The MSP for aberrant gene promoter methylation was performed as described in detail previously [
30]. Each sample was amplified with two sets of primers, one set for methylated DNA (methylated MSP) and one set for unmethylated DNA (unmethylated MSP). Treatment of DNA with bisulfite for conversion of unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed with the EpiTect Bisulfite Kit kit (QIAGEN, Germany). Details of primers and conditions for MSP of
miR-9-1,
miR-9-2 and
miR-9-3 were given in Additional file
1: Table S1.
Quantitative bisulfite pyrosequencing
DNA was treated with bisulfite and used as template. Primers for pyrosequencing were used to amplify the promoter region, which was overlapped with the amplicon of MSP. Primers were designed using PSQ Assay Design software (Biotage). Forward primer: 5′-GAAGGGGGTTGGGATTTGA-3′; Reverse primer: 5′-ATTTCTCCCCTACTCCCC-3′; condition: 2mM/61°C/50X. A stretch of DNA with 9 adjacent CpG dinucleotides was pyrosequenced by sequencing primer: 5′-ATGGGAGTTTGTGAT-3′.
5-Aza-2′-deoxycytidine (5-AzadC) treatment
I83-E95 and WAC3CD5+ cells at log-phase were cultured in six-well plates at a density of 1 × 10
6 cells/ml, with 0.5 μM of 5-AzadC (Sigma-Aldrich, St. Louis, MO, USA) for 5 days respectively, as described [
31]. Fresh 5-AzadC was replaced every 24 hours. I83-E95 and WAC3CD5+ cells on day 0 and day 5 of 5-AzadC treatment were harvested respectively.
Quantification of pri-miR-9-3 and miR-9
According to the manufacturer’s instructions, total RNA was isolated using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). For quantification of
pri-miR-9-3, miRNA was reversely transcribed by the QuantiTect Reverse Transcription Kit (QIAGEN, Valencia, CA), and quantified using the TaqMan Pri-miRNA Assay (ABI, Foster City, CA). GAPDH was used as reference for data analysis using the 2
-∆∆CT method [
32]. Moreover,
miR-9 was quantified by the TaqMan MicroRNA RT Kit, and TaqMan MicroRNA Assay Kit. RNU48 was chosen as reference using the 2
-∆∆CT method [
32].
Overexpression of miR-9 precursor
According to the manufacturers’ instructions, precursor
miR-9 mimic (final concentration 100 nM) (Ambion, Austin, TX, USA) was transfected into 1 × 10
6 I83-E95 cells and WAC3CD5+ cells respectively, using X-tremeGENE siRNA Transfection Reagent (Roche, Basel, Switzerland), as described [
33]. Non-targeting oligonucleotide mimic was used as the negative control.
Cell proliferation, viability analyses
The MTT method was used to determine cellular proliferation [
34]. Cells were seeded in a 96-well microtitre plate at 2.5 × 10
4/well in 100 μl of medium. At the assay test time point 48 hours after transfection, 10 μl of 5 mg/ml MTT reagent was added to each well and incubated for 4 hours. Then each well was added with 100 μl dimethyl sulfoxide (DMSO), followed by the measurement of absorbance at 550 nm with reference to 650 nm. Cellular viability assay was performed by the Trypan blue dye exclusion assay under microscope. Dead cells (%) = (total number of dead cells per microscopic field/ total number of cells per microscopic field) × 100. Five random microscopic fields were counted in each sample.
Cellular apoptosis analysis
Cell apoptosis was assessed by flow cytometry using FITC Annexin V and PI staining as described previously [
35]. FITC Annexin V Apoptosis Detection Kit I (BD-Pharmingen) was used here. 1 × 10
6 I83-E95 or WAC3CD5+ cells were washed with cold PBS and resuspended in 100 μl binding buffer with 5 ul of Annexin V and 5 ul PI, and then incubated for 15 minutes at room temperature in the dark. After adding 400 μl binding buffer to each tube, samples were analyzed by flow cytometry (BD FACS Canto II). FITC Annexin V positive, PI negative or FITC Annexin V positive, PI positive cells were counted as apoptosis cells.
Western blot for NFκB1
After 48 hours transfection, I83-E95 cells were harvested and lysed in RIPA buffer (50 mM Tris- HCl, pH 7.4, 150 mM NaCl, 0.2% SDS, 1% Triton X-100, 2 mM EDTA). Protein lysates were separated on 10% SDS-PAGE and blotting were performed on a 0.2 μm nitrocellulose membrane (Bio-Rad, Hercules, CA). The membranes were incubated with NFκB1 (1:1000; Santa Cruz, CA) or anti-actin (1:5000; Sigma-Aldrich, USA) primary antibody at 4°C overnight. Then membranes were washed and incubated with anti-rabbit horseradish peroxidase conjugate secondary antibody at room temperature for 1 hour. Protein signals were detected by ECL plus Western blotting detection reagents (Amersham Biosciences, Buckinghamshire, UK) and exposed to X-ray film.
Statistical analysis
In CLL, the association of miR-9-3 methylation status with continuous variables (such as mean age, mean lymphocyte counts, diagnostic hemoglobin or platelet counts) and categorical variables (gender, Rai stage or high-risk karyotypes) were analyzed by student’s t-test and chi-square test (or Fisher’s exact test) respectively. OS is assessed from the date of diagnosis to the date of last follow-up or death. OS of patients with limited Rai stage (stages 0, I and II) was compared with those with advanced Rai stage (stages III and IV). Furthermore, OS of patients with high-risk karyotypes [del(17p), del(11q) or trisomy 12] was compared to those with standard-risk karyotypes [del(13q), normal karyotype or other karyotypic changes]. The mean values of MTT assay, Trypan blue exclusion assay, FITC Annexin V and PI staining apoptosis analysis in I83-E95 or WAC3CD5+ cells transfected with precursor miR-9 mimic were compared to those transfected with the scrambled oligo by student’s t-test. Survival was plotted by the Kaplan–Meier method and compared by the log-rank test. All P values were two-sided.
Discussion
Despite the retrospective nature, this cohort of patients had previously been shown to be typical of CLL, in that patients pursued an indolent course with prolonged survival, which was adversely impacted by advanced Rai stage and high-risk karyotypes.
Firstly,
miR-9-3 and
miR-9-1 methylation in CLL cell lines was tumor-specific as evidenced by the absence of methylation in normal peripheral blood buffy coat and CD19-sorted B-cells, and normal bone marrow cells. By contrast,
miR-9-2 methylation appeared to occur both in normal CD19 + ve B-cells and CLL B-cells, and hence this pattern of methylation is tissue-specific but not tumor-specific [
36]. Similarly, miRNAs such as
miR-127 and
miR-373 have been shown hypermethylated in both normal and tumor cells, and hence represent tissue-specific but not tumor-specific miRNA methylation [
36]. On the other hand, a recent study of miRNAs deregulated by either gene hypo- or hyper-methylation in CLL showed methylation of
miR-9-2 in CLL [
37]. This disparity might be accounted by the use of quantitative MassARRAY in their study, in which aberrant methylation of
miR-9-2 was defined as a certain level of methylation above that occurring in normal controls. However, as Chinese have a much lower incidence of CLL, whether
miR-9-2 methylation in Caucasian patients arose from a primary biological difference between the Asian and Western could not be excluded [
38,
39].
Furthermore, upon the 5-AzadC treatment of I83-E95 and WAC3CD5+ cells, both of which were homozygously methylated for miR-9-3, emergence of U-MSP signal, and thus demethylation of miR-9-3 promoter, was correlated with pri-miR-9-3 re-expression. Therefore, miR-9-3 methylation is frequent in CLL cell lines, leading to the reversible miRNA silencing.
Moreover, tumor suppressor activity of
miR-9-3 was demonstrated in CLL. We showed that restoration of
miR-9 in I83-E95 cells harboring complete methylation of
miR-9-3 led to reduced cellular proliferation and enhanced apoptosis. In addition, overexpression of
miR-9 led to downregulation of NFκB1 (P105/P50), consistent with previous data that NFκB1 was a direct target of
miR-9 by translational repression in ovarian cancer cells [
24]. On the other hand, while the tumor suppressor role of
miR-9, due to epigenetically downregulation, has been reported in some cancers [
19,
40‐
43].
miR-9 has also been implicated as an oncomir in other cancers. For example, in breast cancer cells, as a metastasis-promoting miRNA,
miR-9 led to enhanced cell motility and hence invasiveness by targeting E-cadherin [
21]. In glioblastoma cells, overexpression of
miR-9/
9* could inhibit the expression of the tumor suppressor gene
CAMTA1, leading to enhanced cell survival, implying that it might be an oncomir [
23].
Interesting, we noted the significant association of
miR-9-3 methylation with advanced Rai stage (≥ stage 2) in CLL patients, which is a poor risk factor for survival. Similarly,
miR-9-3 methylation has been shown to be associated with metastatic recurrence in renal cell carcinoma [
40], in addition to shorter disease-free and overall survivals in squamous cell lung cancer [
41]. However, apart from Rai stage, there was no association between the
miR-9-3 methylation and other clinical parameters including age, gender, diagnostic hemoglobin, lymphocyte counts, high-risk karyotypic aberrations or survival. Given the small number of samples in our cohort, the possible role of
miR-9-3 as a prognostic marker by impacting on survival requires validation in a larger scale study.
Constitutive activation of NFκB have played roles in carcinogenesis, including stimulating cell proliferation, inhibiting cell apoptosis and increasing tumor metastasis [
44]. Upon canonical NFκB activation by cytokines such as IL-1, IL-2 or TNFα, NFκB (a dimer comprising P50:P65) is released from the NFκB-IκBα complex, allowing nuclear translocation of NFκB and signaling activation [
45,
46].
NFκB1 gene encodes 2 functional proteins, the cytoplasmic precursor P105 and the corresponding processed product P50. In HEK-293 cells and ovarian cancer ES-2 cells,
NFκB1 has been shown to be a direct target of
miR-9 by luciferase assay [
24,
47]. Moreover,
miR-9 overexpression suppressed tumor cell proliferation in association with repression of NFκB pathway, thereby confirming the tumor suppressive role of
miR-9 via the regulation of NFκB signaling in ovarian cancer [
24]. Similarly, constitutive activation of NFκB activity has been demonstrated in CLL cells, conferring survival benefit through induction of a multitude of anti-apoptotic proteins including X-linked inhibitor of apoptosis protein (XIAP), FLICE-like inhibitory protein (FLIP) and members of the BCL2 family (BCL-XL and A1/BFL1) [
48,
49]. In our study, we also showed that
miR-9 overexpression in I83-E95 cells resulted in downregulation of NFκB1 (P105/P50) protein. Therefore,
miR-9-3 methylation may account for constitutive upregulation of NFκB1, and hence constitutive NFκB activation in CLL patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CSC, YLK conceived of the study, and participated in its design. CSC, CSBK, KFW performed in acquisition of data. LQW performed the experiments. CSC, LQW, KYW participated in data analysis. LQW, CSC, YLK, CSBK, KFW, KYW, MF, GAC are involved in manuscript drafting and revisions. All authors read and approved the final manuscript.